251 related articles for article (PubMed ID: 24132639)
1. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.
Desnoyers LR; Vasiljeva O; Richardson JH; Yang A; Menendez EE; Liang TW; Wong C; Bessette PH; Kamath K; Moore SJ; Sagert JG; Hostetter DR; Han F; Gee J; Flandez J; Markham K; Nguyen M; Krimm M; Wong KR; Liu S; Daugherty PS; West JW; Lowman HB
Sci Transl Med; 2013 Oct; 5(207):207ra144. PubMed ID: 24132639
[TBL] [Abstract][Full Text] [Related]
2. In vivo imaging of protease activity by Probody therapeutic activation.
Wong KR; Menendez E; Craik CS; Kavanaugh WM; Vasiljeva O
Biochimie; 2016 Mar; 122():62-7. PubMed ID: 26546838
[TBL] [Abstract][Full Text] [Related]
3. Probody therapeutics for targeting antibodies to diseased tissue.
Polu KR; Lowman HB
Expert Opin Biol Ther; 2014 Aug; 14(8):1049-53. PubMed ID: 24845630
[TBL] [Abstract][Full Text] [Related]
4. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
5. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
[TBL] [Abstract][Full Text] [Related]
7. Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology.
Autio KA; Boni V; Humphrey RW; Naing A
Clin Cancer Res; 2020 Mar; 26(5):984-989. PubMed ID: 31601568
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
[TBL] [Abstract][Full Text] [Related]
9. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
10. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by
Chomet M; Schreurs M; Nguyen M; Howng B; Villanueva R; Krimm M; Vasiljeva O; van Dongen GAMS; Vugts DJ
Theranostics; 2020; 10(13):5815-5828. PubMed ID: 32483421
[TBL] [Abstract][Full Text] [Related]
11. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
12. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
[TBL] [Abstract][Full Text] [Related]
14. A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.
Boustany LM; LaPorte SL; Wong L; White C; Vinod V; Shen J; Yu W; Koditek D; Winter MB; Moore SJ; Mei L; Diep L; Huang Y; Liu S; Vasiljeva O; West J; Richardson J; Irving B; Belvin M; Kavanaugh WM
Cancer Res; 2022 Nov; 82(22):4288-4298. PubMed ID: 36112781
[TBL] [Abstract][Full Text] [Related]
15. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.
Aerts HJ; Dubois L; Hackeng TM; Straathof R; Chiu RK; Lieuwes NG; Jutten B; Weppler SA; Lammering G; Wouters BG; Lambin P
Radiother Oncol; 2007 Jun; 83(3):326-32. PubMed ID: 17531336
[TBL] [Abstract][Full Text] [Related]
18. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
19. Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes.
Vasiljeva O; Menendez E; Nguyen M; Craik CS; Michael Kavanaugh W
Sci Rep; 2020 Apr; 10(1):5894. PubMed ID: 32246002
[TBL] [Abstract][Full Text] [Related]
20. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
Lammerts van Bueren JJ; Bleeker WK; Bøgh HO; Houtkamp M; Schuurman J; van de Winkel JG; Parren PW
Cancer Res; 2006 Aug; 66(15):7630-8. PubMed ID: 16885363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]